
What is claimed is:

1. Crystalline Compound (I):



(I),

which has an X-ray powder diffraction pattern comprising peaks at 18.1, 20.3, 22.9, 24.0, and 26.3 ±0.2° 2θ.

2. The crystalline compound (I) of claim 1, wherein the crystalline compound comprises less than 10% by weight of any other crystalline Compound (I).


3. The crystalline compound (I) of claim 2, wherein the crystalline compound (I) comprises less than 5% by weight of any other crystalline compound (I).

4. The crystalline Compound (I) of claim 1, wherein the crystalline compound comprises less than 10% by weight of amorphous Compound (I).

5. The crystalline compound (I) of claim 4, wherein the crystalline compound (I) comprises less than 5% by weight of amorphous Compound (I).

6. The crystalline compound (I) of claim 1, which has a DSC endotherm at about 175.8 °C.

7. The crystalline compound (I) of claim 1, wherein the crystalline compound (I) comprises less than 100 ppm of a compound of Formula (II),



as determined by GC/MS.

8. The crystalline compound (I) of claim 7, wherein the crystalline compound (I) comprises less than 50 ppm of a compound of Formula (II).


9. The crystalline compound (I) of claim 8, wherein the crystalline compound (I) comprises less than 10 ppm of a compound of Formula (II).

10. The crystalline Compound (I) of claim 1, wherein the crystalline Compound (I) is at least 99.5% pure as measured by HPLC.

11. A pharmaceutical composition comprising the crystalline compound (I) of claim 1.

12. An oral dosage form comprising the crystalline compound (I) of claim 1.

13. Crystalline Compound (I),




(I),

which has an X-ray powder diffraction pattern as shown in FIG. 1.

14. A pharmaceutical composition comprising the crystalline compound (I) of claim 13.

15. Crystalline Compound (I),



(I),

prepared by crystallization from a solution comprising acetone and Compound (I), and

wherein said crystalline Compound (I) has an X-ray powder diffraction pattern comprising peaks at 18.1, 20.3, 22.9, 24.0, and 26.3 ±0.2° 2θ.

16. The crystalline compound (I) of claim 15, which has a DSC endotherm at about 175.8 °C.

17. A pharmaceutical composition comprising the crystalline compound (I) of claim 15.

18. A pharmaceutical composition comprising the crystalline compound (I) of claim 7.

19. A pharmaceutical composition comprising the crystalline compound (I) of claim 10.